TPM3 and Ataxia: The description of ‘ataxia’ with next-generation TRK inhibition supports this hypothesis [30], and the more pronounced nature of this side-effect may be related to the more potent inhibition of wild-type TRK with these drugs (compared with first-generation TRK inhibitors).